Fulcrum Halts Development of SCD Candidate Pociredir, Sets Strategic Review

The FDA's concerns, which the agency raised with Fulcrum executives at a recent end-of-phase meeting, stemmed from an unexpectedly high rate of secondary blood cancers seen with another PRC2 inhibitor—Ipsen’s Tazverik® (tazemetostat), indicated to treat follicular lymphoma and epithelioid sarcoma, the company disclosed, based on meeting minutes received May 28. The post Fulcrum Halts Development of SCD Candidate Pociredir, Sets Strategic Review appeared first on GEN - Genetic Engineering and Biotechnology News.